Ombitasvir

Identification

Summary

Ombitasvir is a direct acting antiviral agent used in combination with other antiviral agents for the treatment of Hepatitis C Virus (HCV) infections.

Brand Names

Viekira Pak

Generic Name

Ombitasvir

DrugBank Accession Number

DB09296

Background

Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients ⁸. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Ombitasvir. Ombitasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly ^Label. The barrier for develoment of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs ⁵.

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Ombitasvir as a first line therapy option when used in combination with other antivirals for genotypes 1a, 1b, and 4 ⁸. Depending on the genotype, Ombitasvir is often used in combination with other antivirals such as Dasabuvir, Paritaprevir, Ritonavir, and Ribavirin with the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality ⁶. Treatment with direct acting antivirals such as Ombitasvir is associated with very minimal side effects, with the most common being headache and fatigue ^Label. Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon-based regimens, which were limited by infusion site reactions, reduced blood count, and neuropsychiatric effects ⁷.

Ombutasvir first came on the market as a fixed-dose combination product with Dasabuvir, Paritaprevir, and Ritonavir as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis.

Ombutasvir is also available as a fixed-dose combination product with Paritaprevir and Ritonavir as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis.

In Canada, Ombutasvir is also available as a fixed-dose combination product with Dasabuvir, Paritaprevir, and Ritonavir as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis.

Type

Small Molecule

Groups

Approved, Investigational

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Ombitasvir (DB09296)

×

Close

Weight

Average: 894.127
Monoisotopic: 893.505112145

Chemical Formula

C₅₀H₆₇N₇O₈

Synonyms

• dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate
• Ombitasvir

External IDs

• ABT 267
• ABT-267
• ABT267

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

When used in combination with Paritaprevir and Ritonavir (as the fixed dose product Technivie), Ombitasvir is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis ⁹.

When used in combination with Paritaprevir, Ritonavir, and Dasabuvir (as the fixed dose product Viekira Pak), Ombitasvir is indicated for the treatment of HCV genotype 1b and ,when combined with Ribavirin, for the treatment of HCV genotype 1a ^Label

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Used in combination to treat	Chronic hepatitis c genotype 1a	Regimen in combination with: Dasabuvir (DB09183), Paritaprevir (DB09297), Ritonavir (DB00503), Ribavirin (DB00811)	••••••••••••
Used in combination to treat	Chronic hepatitis c genotype 1b	Combination Product in combination with: Ritonavir (DB00503), Dasabuvir (DB09183), Paritaprevir (DB09297)	••••••••••••
Used in combination to treat	Without cirrhosis chronic hepatitis c genotype 4	Regimen in combination with: Paritaprevir (DB09297), Ritonavir (DB00503), Ribavirin (DB00811)	••••••••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Ombitasvir is classified as a direct acting antiviral and acts against HCV to inhibit viral replication ^Label.

Mechanism of action

Ombitasvir is an inhibitor of the HCV non-structural protein 5A. While the precise role of this protein is unknown, it is essential to viral replication and virion assembly ^Label. Potential modes of action of NS5A inhibitors like Elbasvir include blocking signaling interactions, redistribution of NS5A from the endoplasmic reticulum to the surface of lipid droplets, and modification of the HCV replication complex ⁵.

Target	Actions	Organism
ANonstructural protein 5A	inhibitor	Hepatitis C Virus

Absorption

Ombitasvir reaches peak plasma concentration 5 hours after administration ^Label. It has an absolute bioavailability of 48%. Taking ombitasvir with high or normal fat meals increases exposure by 1.76 or 1.82 fold respectively.

Volume of distribution

Ombitasvir has a volume of distribution at steady state of 173 liters ^Label.

Protein binding

Ombitasvir is 99.9% bound to human plasma proteins ^Label.

Metabolism

Ombitasvir is mainly metabolized by amide hydrolysis followed by CYP2C8-mediated oxidative metabolism ^Label.

Route of elimination

Ombitasvir is mainly excreted in the feces (90.2%) with very little excreted in the urine (1.91%) ^Label. 87.8% and 0.03% of the dose excreted in the feces and urine respectively is present as the parent compound.

Half-life

Ombitasvir has a half life of elimination of 21-25 hours ^Label

Clearance

Clearance of Ombitasvir has not been determined.

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

The most common adverse effects of Viekira Pak either in combination with or without Ribavirin were pruritus, nausea, insomnia, and asthenia ^Label. The most common adverse effects of Technivie with or without Ribavirin were asthenia, fatigue, nausea, insomnia and pruritus ⁹.

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abacavir	The metabolism of Abacavir can be decreased when combined with Ombitasvir.
Abatacept	The metabolism of Ombitasvir can be increased when combined with Abatacept.
Abemaciclib	Abemaciclib may decrease the excretion rate of Ombitasvir which could result in a higher serum level.
Abiraterone	The metabolism of Ombitasvir can be decreased when combined with Abiraterone.
Abrocitinib	The serum concentration of Ombitasvir can be increased when it is combined with Abrocitinib.

Food Interactions

• Avoid St. John's Wort.
• Take with food.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Ombitasvir heminonahydrate	EQE3I70J3W	1456607-70-7	AWMWWEBJJCSJHI-MVJJBPFMSA-N

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Holkira Pak	Ombitasvir (12.5 mg) + Dasabuvir sodium monohydrate (250 mg) + Paritaprevir (75 mg) + Ritonavir (50 mg)	Kit; Tablet	Oral	Abbvie	2015-01-06	2018-08-15
Technivie	Ombitasvir (12.5 mg) + Paritaprevir (75 mg) + Ritonavir (50 mg)	Tablet	Oral	Abbvie	2015-11-24	2018-07-30
Technivie	Ombitasvir heminonahydrate (12.5 mg/1) + Paritaprevir dihydrate (75 mg/1) + Ritonavir (50 mg/1)	Tablet	Oral	AbbVie Inc.	2015-07-24	2019-03-14
Viekira Pak	Ombitasvir heminonahydrate (12.5 mg/1) + Dasabuvir sodium monohydrate (250 mg/1) + Paritaprevir dihydrate (75 mg/1) + Ritonavir (50 mg/1)	Kit; Tablet, film coated	Oral	AbbVie Inc.	2014-12-19	Not applicable
VIEKIRA PAK TABLET	Ombitasvir (12.5 mg) + Dasabuvir (250 mg) + Paritaprevir (75 mg) + Ritonavir (50 mg)	Tablet, film coated	Oral	ABBVIE PTE. LTD.	2015-11-02	Not applicable

Categories

ATC Codes

J05AP53 — Ombitasvir, paritaprevir and ritonavir

• J05AP — Antivirals for treatment of HCV infections
• J05A — DIRECT ACTING ANTIVIRALS
• J05 — ANTIVIRALS FOR SYSTEMIC USE
• J — ANTIINFECTIVES FOR SYSTEMIC USE

J05AP52 — Dasabuvir, ombitasvir, paritaprevir and ritonavir

• J05AP — Antivirals for treatment of HCV infections
• J05A — DIRECT ACTING ANTIVIRALS
• J05 — ANTIVIRALS FOR SYSTEMIC USE
• J — ANTIINFECTIVES FOR SYSTEMIC USE

Drug Categories

• Amides
• Amines
• Amino Acids
• Amino Acids, Branched-Chain
• Amino Acids, Cyclic
• Amino Acids, Essential
• Amino Acids, Peptides, and Proteins
• Aniline Compounds
• Antiinfectives for Systemic Use
• Antiviral Agents
• Antivirals for Systemic Use
• Antivirals for treatment of HCV infections
• BCRP/ABCG2 Substrates
• Cytochrome P-450 CYP2C8 Substrates
• Cytochrome P-450 Substrates
• Direct Acting Antivirals
• Hepatitis C Virus NS5A Inhibitor
• Imino Acids
• P-glycoprotein substrates
• Treatments for Hepatitis C
• UGT1A1 Inhibitors

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Dipeptides

Alternative Parents

Valine and derivatives / Proline and derivatives / Alpha amino acid amides / Phenylpyrrolidines / Phenylpropanes / Anilides / Pyrrolidinecarboxamides / Aniline and substituted anilines / N-arylamides / N-acylpyrrolidines / Dialkylarylamines / Aralkylamines / Tertiary carboxylic acid amides / Pyrroles / Methylcarbamates / Secondary carboxylic acid amides / Organic carbonic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Carbonyl compounds / Hydrocarbon derivatives

show 12 more

Substituents

1-phenylpyrrolidine / 2-phenylpyrrolidine / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-dipeptide / Amine / Amino acid or derivatives / Anilide / Aniline or substituted anilines / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxamide group / Dialkylarylamine / Hydrocarbon derivative / Methylcarbamate / Monocyclic benzene moiety / N-acylpyrrolidine / N-arylamide / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organoheterocyclic compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Phenylpropane / Proline or derivatives / Pyrrole / Pyrrolidine / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine-2-carboxamide / Secondary carboxylic acid amide / Tertiary aliphatic/aromatic amine / Tertiary amine / Tertiary carboxylic acid amide / Valine or derivatives

show 31 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

carbamate ester, dipeptide, pyrrolidines, ring assembly, aromatic amide (CHEBI:85183)

Affected organisms

Not Available

Chemical Identifiers

UNII

2302768XJ8

CAS number

1258226-87-7

InChI Key

PIDFDZJZLOTZTM-KHVQSSSXSA-N

InChI

InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1

IUPAC Name

methyl N-[(2S)-1-[(2S)-2-({4-[(2S,5S)-1-(4-tert-butylphenyl)-5-{4-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidine-2-amido]phenyl}pyrrolidin-2-yl]phenyl}carbamoyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

SMILES

COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1

References

General References

1. Shen J, Serby M, Surber B, Lee AJ, Ma J, Badri P, Menon R, Kavetskaia O, de Morais SM, Sydor J, Fischer V: Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans. Drug Metab Dispos. 2016 Aug;44(8):1148-57. doi: 10.1124/dmd.115.067496. Epub 2016 May 13. [Article]
2. DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM: Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57. doi: 10.1021/jm401398x. Epub 2014 Jan 15. [Article]
3. Keating GM: Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection. Drugs. 2016 Aug;76(12):1203-11. doi: 10.1007/s40265-016-0612-1. [Article]
4. Macdonald A, Harris M: Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol. 2004 Sep;85(Pt 9):2485-502. [Article]
5. Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x. [Article]
6. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [Article]
7. Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997 Sep;26(3 Suppl 1):112S-121S. [Article]
8. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
9. Dailymed: Technivie [Link]

External Links

KEGG Drug

D10745

PubChem Compound

54767916

PubChem Substance

310265188

ChemSpider

31136214

BindingDB

50453112

RxNav

1597371

ChEBI

85183

ChEMBL

CHEMBL3127326

ZINC

ZINC000150601177

PharmGKB

PA166163409

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Ombitasvir

FDA label

Download (540 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Treatment	Hepatitis C Virus (HCV) Infection	1
4	Completed	Prevention	Hepatitis C Virus (HCV) Infection	1
4	Completed	Treatment	Chronic Hepatitis C Virus (HCV) Infection	3
4	Completed	Treatment	Chronic Hepatitis C Virus (HCV) Infection / Chronic Kidney Disease (CKD)	1
4	Completed	Treatment	End Stage Renal Disease (ESRD) / HCV Coinfection	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Tablet	Oral
Kit; tablet, film coated	Oral
Tablet, film coated	Oral	250 mg
Kit; tablet	Oral
Tablet, film coated	Oral
Tablet, coated	Oral

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US6703403	Yes	2004-03-09	2016-12-26
US6037157	Yes	2000-03-14	2016-12-26
US7364752	Yes	2008-04-29	2021-05-10
US7148359	Yes	2006-12-12	2020-01-19
US8268349	Yes	2012-09-18	2025-02-25
US8399015	Yes	2013-03-19	2025-02-25
US9139536	No	2015-09-22	2028-11-09
US8685984	No	2014-04-01	2032-09-04
US8466159	No	2013-06-18	2032-09-04
US8642538	No	2014-02-04	2029-09-10
US8501238	No	2013-08-06	2028-09-17
US8680106	No	2014-03-25	2032-09-04
US8492386	No	2013-07-23	2032-09-04
US8188104	No	2012-05-29	2029-05-17
US9006387	No	2015-04-14	2030-06-10
US9044480	No	2015-06-02	2031-04-10
US8686026	No	2014-04-01	2031-06-09
US8420596	Yes	2013-04-16	2031-10-10
US8691938	No	2014-04-08	2032-04-13
US9629841	No	2017-04-25	2033-10-18
US9333204	No	2016-05-10	2035-01-02
US9744170	No	2017-08-29	2035-01-02
US10105365	No	2018-10-23	2035-01-02
US10201584	No	2019-02-12	2032-05-17
US10201542	No	2019-02-12	2033-10-18
US10201541	No	2019-02-12	2032-05-17

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00193 mg/mL	ALOGPS
logP	5.72	ALOGPS
logP	7.49	Chemaxon
logS	-5.7	ALOGPS
pKa (Strongest Acidic)	12.77	Chemaxon
pKa (Strongest Basic)	2.16	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	7	Chemaxon
Hydrogen Donor Count	4	Chemaxon
Polar Surface Area	178.72 Å2	Chemaxon
Rotatable Bond Count	16	Chemaxon
Refractivity	250.79 m3·mol-1	Chemaxon
Polarizability	99.1 Å3	Chemaxon
Number of Rings	6	Chemaxon
Bioavailability	0	Chemaxon
Rule of Five	No	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	Yes	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-004r-7310024960-fdc471605d98f4edd073
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0089-1000000960-e439bbe29c2e6c7b977c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0aca-6300001950-0e807e952385341ae63e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-001i-7200000790-000db19a99e402c9eeaf
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-006x-9300003480-66e9b407c2bc861bb64e
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0fl1-9811010720-61a317dc49ea1fe39092

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	301.35345	predicted	DeepCCS 1.0 (2019)
[M+H]+	303.07718	predicted	DeepCCS 1.0 (2019)
[M+Na]+	309.40616	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Nonstructural protein 5A

Kind

Protein

Organism

Hepatitis C Virus

Pharmacological action

Yes

Actions

Inhibitor

General Function

Zinc ion binding

Specific Function

Not Available

Gene Name

NS5A

Uniprot ID

Q5L478

Uniprot Name

Nonstructural protein 5A

Molecular Weight

48598.34 Da

References

1. DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM: Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57. doi: 10.1021/jm401398x. Epub 2014 Jan 15. [Article]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at October 30, 2015 15:54 / Updated at March 04, 2021 09:26